Histone deacetylases (HDACs) are evolutionary conserved enzymes which operate by
removing acetyl groups from histones and other protein regulatory factors, with functional …

Gene mutations are strongly associated with tumor progression and are well known in
cancer development. However, recently discovered epigenetic alterations have shown the …

The therapeutic action of drugs is predicated on their physical engagement with cellular
targets. Here we describe a broadly applicable method using bioluminescence resonance …

Because γ-amino acids generally undergo rapid self-cyclization upon esterification on the
carboxyl group, for example, γ-aminoacyl-tRNA, there are no reports of the ribosomal …

Aberrant expression of epigenetic regulators of gene expression contributes to initiation and
progression of cancer. During recent years, considerable research efforts have focused on …

The remarkable complexity of cancer involving multiple mechanisms of action and specific
organs led researchers Hanahan and Weinberg to distinguish biological capabilities …

Epigenetic abnormalities including abnormal histone methyltransferase activity contribute to
breast cancer pathogenesis. An example is over expression of the polycomb repressive …

Background: Over the last decade, several drugs that inhibit class I and/or class II histone
deacetylases (HDACs) have been identified, including trichostatin A, the cyclic depsipeptide …

Histone acetylation constitutes an epigenetic mark for transcriptional regulation. Here we
developed a fluorescent probe to visualize acetylation of histone H4 Lys12 (H4K12) in living …

Psammaplin A (11c) is a marine metabolite previously reported to be a potent inhibitor of two
classes of epigenetic enzymes: histone deacetylases and DNA methyltransferases. The …